Glucagon (19-29) (human, rat, porcine) trifluoroacetate salt

Names

[ Name ]:
Glucagon (19-29) (human, rat, porcine) trifluoroacetate salt

[Synonym ]:
Miniglucagon (huMan,rat,porcine)
Glucagon (19-29) (human,rat,porcine)
GLUCAGON (19-29),HUMAN
AQDFVQWLMNT
glucagon(19-29
Glucagon (19-29) (huMan,rat,porcine) Miniglucagon (huMan,rat,porcine)
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR
GLUCAGON (19-29),BOVINE,HUMAN,PORCINE
GLUCAGON (19-29) (HUMAN,BOVINE,PORCINE)
Glucagon (19-29), human

Biological Activity

[Description]:

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

Peptides

[Target]

Insulin secretion[1]

[In Vitro]

Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29)[3].

[In Vivo]

Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein[2].

[Animal admin]

Rats[1] To test the effect of miniglucagon (Glucagon (19-29)) on stimulated insulin secretion, 8.3 mM glucose is perfused during the experiments, including a 45-min equilibration period, followed by miniglucagon (1, 10, 100, and 1,000 pM) perfused with or without 1 nM tGLP-1. To study the glucagon and miniglucagon secretion, the glucose concentration is switched from 11 to 3 mM after a 45-min stabilization period, and the peptides secreted are measured by radioimmunoassay[1].

[References]

[1]. Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76.

[2]. Dalle S, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12.

[3]. Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.339 g/cm3

[ Boiling Point ]:
1828.5ºC at 760 mmHg

[ Molecular Formula ]:
C₆₁H₈₉N₁₅O₁₈S

[ Molecular Weight ]:
1352.51000

[ Flash Point ]:
1059.6ºC

[ Exact Mass ]:
1351.62000

[ PSA ]:
582.21000

[ LogP ]:
2.66020

[ Index of Refraction ]:
1.596